Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Avexis Inc (AVXS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,523,237
  • Shares Outstanding, K 31,980
  • Annual Sales, $ 0 K
  • Annual Income, $ -83,010 K
  • 36-Month Beta 2.46
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.70

Price Performance

See More
Period Period Low Period High Performance
1-Month
96.99 +11.61%
on 01/05/18
119.00 -9.03%
on 01/12/18
+2.76 (+2.62%)
since 12/19/17
3-Month
90.73 +19.31%
on 11/13/17
119.00 -9.03%
on 01/12/18
+7.73 (+7.69%)
since 10/19/17
52-Week
50.56 +114.10%
on 01/24/17
119.00 -9.03%
on 01/12/18
+56.71 (+110.03%)
since 01/19/17

Most Recent Stories

More News
AveXis Announces Proposed Public Offering of Common Stock

AveXis, Inc. (NASDAQ:AVXS) today announced that it intends to offer and sell, subject to market conditions, up to $400 million of shares of its common stock in an underwritten public offering. The offering...

AVXS : 108.25 (-1.74%)
AveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular Atrophy

- Company to expand study of AVXS-101 into additional SMA populations including pre-symptomatic, older pediatric Type 2 and Type 3 SMA patients -

AVXS : 108.25 (-1.74%)
REGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular Atrophy

-- AveXis acquires exclusive rights to entire NAV Technology Platform for the development of treatments for SMA

RGNX : 27.10 (-1.63%)
AVXS : 108.25 (-1.74%)
AveXis Announces Alignment with FDA on Next Steps Toward a BLA Submission for AVXS-101 in SMA Type 1

- Company to submit information requested by FDA to the IND on an on-going basis -

AVXS : 108.25 (-1.74%)
AveXis Announces Plan to Initiate Phase 1 Trial in SMA Type 2 Utilizing Intrathecal Delivery of AVXS-101

- The FDA notified AveXis it may initiate the Phase 1 trial in SMA Type 2 based on a review of data provided by the company; trial to commence immediately -

AVXS : 108.25 (-1.74%)
Why AveXis (AVXS) Could Be Positioned for a Slump

AveXis (AVXS) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

AKTX : 3.59 (-0.28%)
AVXS : 108.25 (-1.74%)
AveXis Reports Third Quarter 2017 Financial and Operating Results

- First patient has been dosed in pivotal trial of AVXS-101 for SMA Type 1 -

AVXS : 108.25 (-1.74%)
Biotech Stocks on Investors' Radar -- Aralez Pharma, Arena Pharma, Arrowhead Pharma, and AveXis

If you want a Stock Review on ARLZ, ARNA, ARWR, or AVXS then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. On Tuesday, November 07, 2017, US markets saw...

ARLZ : 1.99 (+1.53%)
ARWR : 6.29 (+9.97%)
ARNA : 35.60 (+4.34%)
AVXS : 108.25 (-1.74%)
AveXis to Report Third Quarter 2017 Financial and Operating Results

AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, will report financial and operating...

AVXS : 108.25 (-1.74%)
AveXis Announces New England Journal of Medicine Publication of Phase 1 Data of AVXS-101 Gene Replacement Therapy in Spinal Muscular Atrophy Type 1

--- As of August 7, 2017, all patients are alive, event-free and have reached at least 20 months of age -

AVXS : 108.25 (-1.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

AveXis, Inc. is a gene therapy company which develops and commercializes treatments for neurological genetic diseases primarily in United States. The Company's product candidate consists of AVXS-101 which is in clinical trial for the treatment of spinal muscular atrophy Type 1, the genetic cause of infant...

See More

Key Turning Points

2nd Resistance Point 112.63
1st Resistance Point 110.44
Last Price 108.25
1st Support Level 105.92
2nd Support Level 103.59

See More

52-Week High 119.00
Last Price 108.25
Fibonacci 61.8% 92.86
Fibonacci 50% 84.78
Fibonacci 38.2% 76.70
52-Week Low 50.56

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.